Skip to main
MNMD

MNMD Stock Forecast & Price Target

MNMD Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mind Medicine Inc. is advancing its late-stage clinical pipeline with promising product candidates, MM120 and MM402, both targeting significant mental health disorders. The Phase 2b data for MM120 indicates statistically significant improvements in generalized anxiety disorder and major depressive disorder, showcasing efficacy that may surpass current standard-of-care treatments. Additionally, preclinical studies for MM402 suggest enhanced pro-social effects compared to conventional MDMA, positioning the company favorably in a growing market with increased acceptance and adoption of psychedelic therapies.

Bears say

Mind Medicine Inc. faces significant clinical and regulatory risks, particularly concerning the potential failure to gain necessary approvals for its novel product candidates, which could adversely affect both the company and its collaborators. Additionally, uncertainty regarding the issuance and protection of key patents poses a threat to the company’s ability to maintain competitive market positioning, which may lead to downward revisions in valuation. Furthermore, the conservative assumptions by management about product performance, as indicated by lower results in the Phase 2 study, contribute to doubts about the viability of its treatment options against existing alternative therapies.

MNMD has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mind Medicine MindMed (MNMD) Forecast

Analysts have given MNMD a Strong Buy based on their latest research and market trends.

According to 9 analysts, MNMD has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mind Medicine MindMed (MNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.